Elena Feinstein

This inventor holds 74 USPTO granted patents and 36 published patent applications, plus 10 CIPO patents and 28 EPO patents, primarily in Oligonucleotide Therapeutics (CPC class C12N). Top assignees: Quark Pharmaceuticals, Inc., Nitto-Denko Corporation, Quark Biotech, Inc.. Active years: 1999-2020.

USPTO Granted Patents = 74 (Patent Applications = 36)

% Patents Active = 36.5

CIPO Patents = 10 (Patent Applications = 6)

EPO Patents = 28 (Patent Applications = 35)

Average Co-Inventor Count = 2.6

ph-index = 12

Forward Citations = 663(Granted Patents)

Forward Citations (Not Self Cited) = 571(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

56 out of 67

Quark Pharmaceuticals, Inc.

patents

8 out of 3,941

Nitto-Denko Corporation

Silence Therapeutics Ag

patents

5. 2 out of 180

Hadasit Medical Research Services and Development Ltd.

patents

6. 2 out of 11

Insight Biopharmaceuticals Ltd.

patents

7. 2 out of 1,374

Washington University

patents

8. 1 out of 1,492

Rutgers, The State University of New Jersey

patents

9. 5 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2020

Loading Chart...

Areas of Expertise:

Oligonucleotide

siRNA

p53 Targeting

HSP47 Modulation

CASP2

Fibrosis Treatment

Cancer Therapy

Neuroprotection

Lung Disease

RTP801 Inhibitors

Alopecia Treatment

Retinoid-Lipid Carrier

74 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10781449 - Double-stranded oligonucleotide molecules targeting p53 and methods of use thereof (2020-09-22),

2. 10570394 - Double-stranded RNA compounds to CASP2 and uses thereof (2020-02-25),

3. 10421962 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2019-09-24),

4. 10196637 - Retinoid-lipid drug carrier (2019-02-05),

5. 10195145 - Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier (2019-02-05),

6. 10144928 - Double stranded oligonucleotide compounds comprising positional modifications (2018-12-04),

7. 10093923 - Modulation of HSP47 expression (2018-10-09),

8. 9993567 - Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases (2018-06-12),

9. 9932578 - Double-stranded oligonucleotide molecules to P53 and methods of use thereof (2018-04-03),

10. 9868953 - Methods and compositions for preventing ischemia reperfusion injury in organs (2018-01-16),

11. 9822362 - Compositions and methods for treating lung disease and injury (2017-11-21),

12. 9796979 - Oligonucleotide modulators of the toll-like receptor pathway (2017-10-24),

13. 9738896 - Methods and compositions for neuroprotection (2017-08-22),

14. 9701961 - Methods for treating eye disorders (2017-07-11),

15. 9611474 - Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof (2017-04-04),

Title: Inventor Elena Feinstein: Revolutionizing Technology in Rehovot

Introduction: Elena Feinstein is a pioneering inventor based in Rehovot, Israel, known for her groundbreaking contributions to the field of technology.

Latest Patents: Elena Feinstein holds several patents in the areas of artificial intelligence, biotechnology, and renewable energy, showcasing her diverse range of expertise and innovation.

Career Highlights: With a career spanning over two decades, Elena Feinstein has worked with leading research institutions and technology companies to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Throughout her career, Elena Feinstein has collaborated with top scientists, engineers, and innovators from around the world, fostering a culture of creativity and excellence in all her projects.

Conclusion: Elena Feinstein's relentless pursuit of innovation and her passion for pushing the boundaries of technology make her a true trailblazer in the field of inventions. Her work continues to inspire the next generation of inventors and shape the future of technology.